Controversy
TD Securities
Goldman Sachs
J.P. Morgan
UBS Global Wealth Management
Edgen
Gabelli
Fortune Business Insights
BCC Research
Research and Markets
+4
Status:Open

Will Annual Global Sales of GLP-1-Based Anti-Obesity and Diabetes Drugs Exceed $100B by 2028?

UNLIKELYLIKELY

Claims

Fortune Business Insights
Fortune Business Insights"The global anti-obesity drugs market size was valued at USD 4.51 billion in 2023 and is projected to grow from USD 6.15 billion in 2024 to USD 37.94 billion by 2032, exhibiting a CAGR of 25.5% during the forecast period (2024-2032)."Nov 10, 2025
Gabelli
Gabelli"We estimate about 12-15 million patients will be using GLP-1 drugs by 2030 across both indications, which translates to the market growing from ~$30B today to ~$80B by 2030."Apr 01, 2025
J.P. Morgan
J.P. Morgan"J.P. Morgan Global Research forecasts that the global incretin market, which includes GLP-1s, will reach $200 billion by 2030."
Goldman Sachs
Goldman Sachs"Goldman Sachs Research forecasts the global market to reach $95 billion by 2030 — lower than its previous estimate of $130 billion."
UBS Global Wealth Management
UBS Global Wealth Management"This [GLP-1 model forecast] translates into $126bn sales by 2029, a 2023-2029 sales CAGR of 30%."Nov 26, 2025
Teneo
Teneo"Analysts project the global GLP-1RA market to reach between $75bn and $140bn by 2030."Jul 06, 2026
CNBC
CNBC"Wall Street is betting big on the burgeoning industry, with estimates suggesting it could be worth upwards of $100 billion by 2030."
Inizio Ignite
Inizio Ignite"The U.S. obesity market alone is expected to exceed $100 billion by 2030."
TradingView
TradingView"TD Cowen has lifted its global GLP-1 sales forecast to $150 billion by 2030."
National Institutes of Health (NIH)
National Institutes of Health (NIH)"The market is projected to reach USD 70.08 billion in 2025 and USD 156.71 billion by 2030."
"The global GLP-1 agonists weight loss drugs market size was estimated at USD 13.84 billion in 2024 and is projected to reach USD 48.84 billion by 2030, growing at a CAGR of 18.54% from 2025 to 2030."Nov 26, 2025
BCC Research
BCC Research"According to BCC Research’s Global GLP-1 Analogues Market report, the market was valued at $54.8 billion in 2024 and is projected to reach $268.4 billion by 2030."
Research and Markets
Research and Markets"The global market for GLP-1 Receptor Agonist was valued at US$51.9 Billion in 2024 and is projected to reach US$137.4 Billion by 2030."
TD Securities
TD Securities"Global GLP-1 sales in 2030 could reach US$139 billion, up from our US$101 billion forecast a little over a year ago."Nov 26, 2025
Edgen
Edgen"The obesity therapeutics market is projected for significant expansion, targeting $20.84 billion by 2033 with a compound annual growth rate of 20.6%."Nov 26, 2025
Harvest ETFs
Harvest ETFs"The GLP-1 drug class boasts projected sales exceeding US $150 billion by 2030."
Len Yaffe
Len Yaffe"I Forecast the US 2030 Anti-Obesity Drug Market to Approximate $150 Billion."
UPS Healthcare
UPS Healthcare"The global GLP-1 market is projected to exceed $100 billion by 2030, growing at a compound annual growth rate (CAGR) of 10.6%."
GlobalData
GlobalData"By 2031, GlobalData expects the obesity market to grow at a strong compound annual growth rate (CAGR) of 32.3%, reaching sales of $173.5 billion by the end of the forecast period."


© 2026 Improve the News Foundation. All rights reserved.Version 7.4.1

© 2026 Improve the News Foundation.

All rights reserved.

Version 7.4.1